Resmed Inc Drc Stock Cash And Equivalents
| RMD Stock | 36.95 0.19 0.52% |
Resmed Inc DRC fundamentals help investors to digest information that contributes to Resmed's financial success or failures. It also enables traders to predict the movement of Resmed Stock. The fundamental analysis module provides a way to measure Resmed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Resmed stock.
| Last Reported | Projected for Next Year | ||
| Cash And Equivalents | 246.3 M | 254.8 M |
Resmed | Cash And Equivalents |
Resmed Inc DRC Company Cash And Equivalents Analysis
Resmed's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Resmed Cash And Equivalents | 273.71 M |
Most of Resmed's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Resmed Inc DRC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Resmed Inc DRC has 273.71 M in Cash And Equivalents. This is 66.66% lower than that of the Health Care Equipment & Supplies sector and 12.82% lower than that of the Health Care industry. The cash and equivalents for all Australia stocks is 89.87% higher than that of the company.
Resmed Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Resmed's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Resmed could also be used in its relative valuation, which is a method of valuing Resmed by comparing valuation metrics of similar companies.Resmed is currently under evaluation in cash and equivalents category among its peers.
Resmed Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 55.56 B | ||||
| Shares Outstanding | 1.47 B | ||||
| Shares Owned By Institutions | 10.45 % | ||||
| Price To Book | 6.47 X | ||||
| Price To Sales | 11.59 X | ||||
| Revenue | 4.69 B | ||||
| Gross Profit | 2.39 B | ||||
| EBITDA | 1.53 B | ||||
| Net Income | 1.02 B | ||||
| Cash And Equivalents | 273.71 M | ||||
| Total Debt | 873.93 M | ||||
| Book Value Per Share | 35.39 X | ||||
| Cash Flow From Operations | 1.4 B | ||||
| Earnings Per Share | 1.22 X | ||||
| Price To Earnings To Growth | 1.74 X | ||||
| Target Price | 41.37 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 55.74 B | ||||
| Total Asset | 6.87 B | ||||
| Retained Earnings | 4.99 B | ||||
| Working Capital | 1.45 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 6.87 B | ||||
| Last Dividend Paid | 1.97 |
About Resmed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Resmed Inc DRC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Resmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Resmed Inc DRC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Resmed Stock Analysis
When running Resmed's price analysis, check to measure Resmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Resmed is operating at the current time. Most of Resmed's value examination focuses on studying past and present price action to predict the probability of Resmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Resmed's price. Additionally, you may evaluate how the addition of Resmed to your portfolios can decrease your overall portfolio volatility.